Related Experiment Video

Updated: Nov 16, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

Targeting POLE2 Creates a Novel Vulnerability in Renal Cell Carcinoma via Modulating Stanniocalcin 1

Chuanjie Zhang1, Yan Shen2, Lili Gao3

  • 1Department of Urology, Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Frontiers in Cell and Developmental Biology
|March 1, 2021
PubMed
Abstract

Insights

DNA polymerase epsilon subunit 2 (POLE2) is overexpressed in kidney cancer, driving tumor growth and poor prognosis. Targeting POLE2 and its downstream gene STC1 may offer new therapeutic strategies for renal cell carcinoma (RCC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell carcinoma (RCC) is a significant global health concern.
  • Understanding the molecular drivers of RCC is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the biological roles and mechanisms of DNA polymerase epsilon subunit 2 (POLE2) in RCC.
  • To explore POLE2 as a potential therapeutic target for RCC.

Main Methods:

  • Analysis of POLE2 expression in TCGA-KIRC and ICGC databases.
  • Immunohistochemistry, gene knockdown (in vitro/in vivo), cell viability, migration, apoptosis assays.
  • Microarray, co-immunoprecipitation, and Western blot to elucidate molecular mechanisms.

Main Results:

  • POLE2 is overexpressed in RCC and linked to poor prognosis.
  • POLE2 knockdown inhibits RCC cell proliferation and migration, and promotes apoptosis.
  • POLE2 regulates stanniocalcin 1 (STC1) and affects key cancer-related signaling pathways.

Conclusions:

  • POLE2 promotes RCC progression by regulating STC1.
  • The POLE2-STC1 axis represents a potential therapeutic target for renal cell carcinoma.
Keywords:
POLE2migrationproliferationrenal cell carcinomastanniocalcin 1

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.0K
Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease12:47

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease

Published on: February 3, 2012

38.9K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K